Business Wire

Fusion Risk Management Announces Strategic Growth Investment from Great Hill Partners

26.4.2023 15:00:00 EEST | Business Wire | Press release

Share

Fusion Risk Management, Inc. (“Fusion” or the “Company”), a leading provider of cloud-based operational resilience, business continuity, and risk management software and services, today announced a strategic growth investment from Great Hill Partners, a leading growth-oriented private equity firm. The majority investment will allow Fusion to enhance its go-to-market and product innovation capabilities, while continuing to accelerate the pursuit of several attractive organic and inorganic growth opportunities. Existing investor Vista Equity Partners (“Vista”) will remain a significant minority shareholder in Fusion, along with Catalyst Investors and Level Equity Management. Financial terms of the transaction were not disclosed.

Fusion has grown rapidly in recent years as organizations in regulated and non-regulated end markets shift from reactive approaches to proactive, real-time frameworks that unite risk across employees, third parties, processes, and technologies. The Company’s leading platform empowers its diverse base of 400+ blue chip customers with the knowledge and workflows they need to better mitigate threats, minimize downtime, maintain operational resilience, and sustain critical operations in the face of unexpected crises such as pandemics, geopolitical events, natural disasters, cyber-attacks, and more.

“As the risk landscape continues to evolve, now more than ever businesses need an agile and flexible operational resilience framework to navigate disruption and drive sustainable growth," said Michael Campbell, CEO of Fusion Risk Management. “Today’s milestone is a testament to Fusion’s capabilities in delivering data-driven, actionable insights that enable customers to develop dynamic plans and proactively address the risks and disruptions that have become ‘business as usual.’ We’re confident that Great Hill will be an invaluable partner as we leverage their deep industry expertise and resources to further unlock the potential of our platform and accelerate our mission to make true business resiliency a reality.”

“Fusion is a clear leader in the risk management space, driving unparalleled value for its customers by providing them with the comprehensive tools they need to become more aware, prepared, and resilient,” said Chris Busby, Managing Director at Great Hill. “The Company fits the exact profile of the type of business we aim to invest in: high-growth companies that are driving transformative change in their industries. Leveraging our significant software and growth-investment experience, Fusion has tremendous potential to capitalize on opportunities ahead amid significant compliance and regulatory tailwinds and to continue deepening its strong, longstanding customer relationships. We’re excited to partner with Michael, the entire management team, and Vista to strengthen Fusion’s position at the forefront of operational resilience and risk management software.”

“Since our partnership began, Fusion and Vista have been focused on transforming the Company into a leading platform through product innovation and scaling its go-to-market capabilities to meet customers’ growing demand to build resilient organizations,” said René Yang Stewart, Co-Head of Vista’s Endeavor Fund and Senior Managing Director. “We are thrilled to continue this momentum by welcoming Great Hill Partners and embarking on the next chapter of Fusion’s growth trajectory.”

In addition to Fusion Risk Management, Great Hill Partners' portfolio of enterprise software companies includes eloomi, BigChange, Auvik, Varicent, Totango, and Intapp, among several others. Prior software investments include Reflexis Systems, Reward Gateway, PlanSource, ZoomInfo, and more.

William Blair & Company served as exclusive financial advisor to Fusion Risk Management. Kirkland & Ellis LLP served as legal advisor to Great Hill Partners and to Fusion.

About Fusion Risk Management, Inc.

Fusion Risk Management is a leading industry provider of cloud-based operational resilience software, encompassing business continuity and disaster recovery, risk management, information technology and security risk management, crisis and incident management, and more. Its solutions empower organizations to make data-driven decisions with a holistic, agile approach and enable them to deliver on their brand promise through disruption. For more information, visit www.fusionrm.com.

About Great Hill Partners

Founded in 1998, Great Hill Partners is a private equity firm targeting investments of $100 million to $500 million in high-growth companies across the software, digital commerce, financial technology, healthcare, and digital infrastructure sectors. With offices in Boston and London, Great Hill has raised over $12 billion of commitments and invested in more than 95 companies, establishing an extensive track record of building long-term partnerships with entrepreneurs and providing flexible resources to help middle-market companies scale. Great Hill has been recognized for its industry leadership, being ranked #3 in the 2022 HEC Paris-Dow Jones Mid-Market Buyout Performance Ranking, which evaluated fund performance of 563 leading private equity firms between 2009-2018. For more information, including a list of all Great Hill investments, visit www.greathillpartners.com.

About Vista Equity Partners

Vista is a leading global investment firm with more than $96 billion in assets under management as of December 31, 2022. The firm exclusively invests in enterprise software, data and technology-enabled organizations across private equity, permanent capital, credit and public equity strategies, bringing an approach that prioritizes creating enduring market value for the benefit of its global ecosystem of investors, companies, customers and employees. Vista's investments are anchored by a sizable long-term capital base, experience in structuring technology-oriented transactions and proven, flexible management techniques that drive sustainable growth. Vista believes the transformative power of technology is the key to an even better future – a healthier planet, a smarter economy, a diverse and inclusive community and a broader path to prosperity. Further information is available at vistaequitypartners.com. Follow Vista on LinkedIn, @Vista Equity Partners, and on Twitter, @Vista_Equity.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Fusion:
Terese Fernandez
Fusion Risk Management
917.640.1016

For Great Hill Partners:
Danya Al-Qattan / Zachary Tramonti / Kevin Siegel
greathill@fgsglobal.com
(212) 687-8080

For Vista Equity Partners:
Brian W. Steel
media@vistaequitypartners.com
(212) 804-9170

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye